Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Jody Cain - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Matkovits - Chief Development Officer Conference Call Participants Greg Fraser - Truist Securities Operator Greetings and welcome to the Matinas BioPharma 2022 Fourth Quarter and Full Year Conference Call. [Operator Instructions] As a reminder, this conference is being ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdicti ...

Financial Data and Key Metrics Changes - The company reported a net loss attributable to common shareholders of approximately $5.5 million or $0.03 per share for Q3 2022, compared to a net loss of $6.8 million or $0.03 per share for the same period in 2021, indicating a reduction in loss [19] - Cash, cash equivalents, and marketable securities at September 30, 2022, were approximately $33.1 million, down from $49.6 million at December 31, 2021, but the company believes this is sufficient to fund operations through 2023 [19] Business Line Data and Key Metrics Changes - The company achieved significant milestones in its MAT2203 program, particularly in the Phase 2 EnACT trial for cryptococcal meningitis, which demonstrated unprecedented survival rates exceeding 90% [9][10] - MAT2203 is positioned for global development and registration, with the European Medicines Agency granting orphan drug designation for the treatment of cryptococcosis [10] Market Data and Key Metrics Changes - The World Health Organization highlighted the rising threat of invasive fungal diseases, particularly among immunocompromised populations, which aligns with the company's focus on developing MAT2203 [10] - The WHO's fungal priority pathogens list includes cryptococcal meningitis and aspergillosis as critical threats, indicating a growing market need for effective treatments [10] Company Strategy and Development Direction - The company plans to initiate a Phase 3 trial for MAT2203 in cryptococcal meningitis in Q1 2023, expanding clinical sites and potentially adding patients to offset unforeseen deaths [15] - The strategy includes securing multiple orphan indications for MAT2203 and maximizing regulatory exclusivities while exploring broader applications for the treatment of invasive fungal infections [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the MAT2203 program's potential, citing strong clinical data and positive feedback from key opinion leaders [10][28] - The company is focused on maintaining a strong cash position and exploring non-dilutive financing options to support its development efforts [21] Other Important Information - The company is actively engaged in licensing discussions with BioNTech regarding the oral delivery of nucleic acids, which is seen as a significant opportunity [20] - The company has expanded its intellectual property portfolio surrounding the LNC platform with multiple new provisional patent filings [22] Q&A Session Summary Question: Can you expand on the feedback from doctors at ID Week regarding MAT2203? - Management noted that survival and safety were key elements that resonated with physicians, highlighting the unprecedented survival rates and safety profile of MAT2203 [26][28] Question: Will the Phase 3 study for invasive fungal infections enroll patients with different infections? - The company plans to enroll patients suffering from various invasive fungal infections, focusing on mucor and aspergillosis, and aims for a streamlined basket study design [30][31] Question: What is the standard treatment protocol with amphotericin for mucor and aspergillosis? - Typically, IV amphotericin is restricted to one to two weeks of treatment due to associated toxicities, followed by step-down therapy with azoles or echinocandins [36] Question: Can you provide details on the harmonization of the EU Phase 3? - Early feedback from the European Medicines Agency was incorporated into the protocol planning for the Phase 3 study, ensuring alignment with regulatory requirements [38] Question: What is the status of the BioNTech collaboration? - Discussions with BioNTech are ongoing, with both parties recognizing the potential value of the collaboration, although specific hurdles remain to be addressed [43]

MATINAS BIOPHARMA Corporate Presentation September 2022 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Peter Vozzo - Investor Relations Representative Jerry Jabbour - Chief Executive Officer Dr. Terry Matkovits - Chief Development Officer Keith Kucinski - Chief Financial Officer Dr. Raphael Mannino - Chief Scientific Officer Dr. Terry Ferguson - Chief Medical Officer Thomas Hoover - Chief Business Officer Conference Call Participants Bert Hazlett - BTIG Operator Hello. And welcome to ...

[PART I - FINANCIAL INFORMATION](index=4&type=section&id=PART%20-%20I%20FINANCIAL%20INFORMATION) [Financial Statements](index=4&type=section&id=Item%201.%20FINANCIAL%20STATEMENTS) The unaudited condensed consolidated financial statements for June 30, 2022, reflect a decrease in total assets to **$52.4 million** and an increased net loss of **$11.9 million**, primarily due to higher R&D expenses and increased cash used in operations [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2022, total assets decreased to **$52.4 million** from **$61.3 million** at year-end 2021, primarily due to a reduction in cash and cash equivalents, while total stockholders' equity also declined Condensed Consolidated Balance Sheet Data (Unaudited) | Account | June 30, 2022 ($) | December 31, 2021 ($) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | 10,398,544 | 21,029,806 | | Total current assets | 41,924,228 | 50,993,321 | | Total assets | 52,415,641 | 61,326,074 | | **Liabilities & Equity** | | | | Total current liabilities | 5,382,315 | 4,348,743 | | Total liabilities | 9,567,104 | 8,833,016 | | Total stockholders' equity | 42,848,537 | 52,493,058 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the six months ended June 30, 2022, the company reported an increased net loss of **$11.9 million**, up from **$9.7 million** in 2021, primarily driven by a significant rise in research and development expenses, partially offset by **$1.06 million** in new revenue Statement of Operations Highlights (Unaudited) | Metric | Three Months Ended June 30, 2022 ($) | Three Months Ended June 30, 2021 ($) | Six Months Ended June 30, 2022 ($) | Six Months Ended June 30, 2021 ($) | | :--- | :--- | :--- | :--- | :--- | | Revenue | 1,062,500 | - | 1,062,500 | 33,333 | | Research and development expense | 4,126,529 | 2,480,764 | 9,104,634 | 5,722,196 | | General and administrative expense | 2,861,421 | 2,308,926 | 5,605,616 | 5,453,936 | | Loss from operations | (5,925,450) | (4,789,690) | (13,647,750) | (11,142,799) | | Net loss | (5,922,584) | (4,791,105) | (11,900,857) | (9,747,425) | | Net loss per share – basic and diluted | (0.03) | (0.02) | (0.05) | (0.05) | [Condensed Consolidated Statements of Cash Flow](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flow) For the six months ended June 30, 2022, net cash used in operating activities significantly increased to **$9.9 million**, while net cash provided by investing activities reversed to a **$0.8 million** outflow, and financing activities sharply decreased to **$87,289** Cash Flow Summary (Unaudited) | Cash Flow Activity | Six Months Ended June 30, 2022 ($) | Six Months Ended June 30, 2021 ($) | | :--- | :--- | :--- | | Net cash used in operating activities | (9,887,912) | (5,515,768) | | Net cash (used in) provided by investing activities | (830,639) | 16,470,652 | | Net cash provided by financing activities | 87,289 | 6,964,994 | | Net (decrease)/increase in cash | (10,631,262) | 17,919,878 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Key notes detail the company's liquidity, with **$38.5 million** in cash and equivalents expected to fund operations through 2023, alongside significant collaboration agreements and manufacturing commitments - The company is a clinical-stage biopharmaceutical firm that has incurred net losses since inception, with an accumulated deficit of approximately **$143.5 million** as of June 30, 2022[21](index=21&type=chunk)[22](index=22&type=chunk) - As of June 30, 2022, the company had approximately **$10.4 million** in cash and cash equivalents and **$28.1 million** in marketable securities, which management believes is sufficient to fund planned operations through 2023[25](index=25&type=chunk) - In April 2022, the company entered into an exclusive research collaboration with BioNTech SE, receiving a **$2.75 million** exclusivity fee, with **$1.1 million** of revenue recognized from this agreement as of June 30, 2022[50](index=50&type=chunk)[52](index=52&type=chunk)[54](index=54&type=chunk) - The company entered into an agreement with Thermo Fisher Scientific in March 2022 for MAT2203 manufacturing, with estimated fees of approximately **$7.7 million** to be incurred over a two-year period[69](index=69&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management discusses the company's strategic focus on advancing its LNC platform and clinical assets, noting increased R&D expenses, **$1.1 million** in new collaboration revenue, and a liquidity position expected to fund operations through 2023 - The company's strategy is focused on advancing its LNC platform technology, progressing MAT2203 for cryptococcal meningitis and MAT2501 for NTM infections, and expanding collaborations like those with Genentech and BioNTech[76](index=76&type=chunk)[79](index=79&type=chunk) - The company expects R&D expenses to continue increasing as product candidates advance to later-stage clinical trials, which are generally more costly[81](index=81&type=chunk) - As of June 30, 2022, the company had cash, cash equivalents, and marketable securities totaling approximately **$38.5 million**, which is expected to fund operations through 2023[99](index=99&type=chunk)[104](index=104&type=chunk) [Results of Operations](index=24&type=section&id=Results%20of%20Operations) For the first six months of 2022, revenue increased to **$1.1 million** due to the BioNTech collaboration, while R&D expenses significantly rose to **$9.1 million** driven by clinical trial and manufacturing costs Comparison of Operating Results (Six Months Ended June 30) | Metric | 2022 ($ in thousands) | 2021 ($ in thousands) | Change Driver | | :--- | :--- | :--- | :--- | | Revenues | 1,063 | 33 | New BioNTech research collaboration in 2022 | | R&D Expenses | 9,105 | 5,722 | Increased clinical trial and manufacturing costs for product candidates | | G&A Expenses | 5,605 | 5,454 | Higher compensation expense | | Sale of NOLs | 1,734 | 1,328 | Sale of NJ state tax credits | [Liquidity and Capital Resources](index=25&type=section&id=Liquidity%20and%20capital%20resources) As of June 30, 2022, the company held **$38.5 million** in cash and equivalents, with **$9.9 million** net cash used in operations for H1 2022, expecting existing funds to last through 2023, with future needs met by external financing - Net cash used in operating activities increased to **$9.9 million** for the first half of 2022, compared to **$5.5 million** in the same period of 2021, due to higher R&D expenses and a larger net loss[100](index=100&type=chunk)[101](index=101&type=chunk) - Net cash provided by financing activities dropped to **$0.1 million** in the first half of 2022 from **$7.0 million** in 2021, primarily due to no At-The-Market (ATM) sales in 2022[103](index=103&type=chunk) - The company anticipates expenses will increase substantially due to ongoing clinical studies for MAT2203 and MAT2501, development of new candidates, and manufacturing scale-up[104](index=104&type=chunk)[106](index=106&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=27&type=section&id=Item%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) This section is not applicable for the company as a smaller reporting company - The company has indicated that quantitative and qualitative disclosures about market risk are not applicable[109](index=109&type=chunk) [Controls and Procedures](index=27&type=section&id=Item%204.%20CONTROLS%20AND%20PROCEDURES) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2022, with no material changes to internal control over financial reporting identified during Q2 2022 - Based on an evaluation as of June 30, 2022, the principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective[110](index=110&type=chunk) - There were no changes in internal control over financial reporting during the second quarter of 2022 that have materially affected, or are reasonably likely to materially affect, internal controls[112](index=112&type=chunk) [PART II - OTHER INFORMATION](index=27&type=section&id=PART%20-%20II%20OTHER%20INFORMATION) [Legal Proceedings](index=27&type=section&id=Item%201.%20LEGAL%20PROCEEDINGS) The company reported no legal proceedings during the period - None[113](index=113&type=chunk) [Risk Factors](index=28&type=section&id=Item%201A.RISK%20FACTORS) No material changes were reported from the risk factors previously disclosed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 - No material changes were reported from the risk factors set forth in the Annual Report on Form 10-K for the fiscal year ended December 31, 2021[115](index=115&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=28&type=section&id=Item%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) The company reported no unregistered sales of equity securities during the period - None[116](index=116&type=chunk) [Other Information](index=28&type=section&id=Item%205.%20OTHER%20INFORMATION) Dr. Raphael Mannino, Chief Scientific Officer, announced his retirement effective December 31, 2022, and will transition to a strategic advisor role under a one-year consulting agreement - Dr. Raphael Mannino, the Chief Scientific Officer, notified the company of his intent to retire effective December 31, 2022[119](index=119&type=chunk) - The company entered into a consulting agreement with Dr. Mannino for at least one year following his retirement, where he will act as a strategic advisor for a monthly rate of **$15,000** and receive an extension on the vesting and exercisability of his outstanding stock options and warrants[119](index=119&type=chunk) [Exhibits](index=28&type=section&id=Item%206.%20EXHIBITS) This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including certifications from the CEO and CFO, and Inline XBRL documents

MATINAS 1 BIOPHARMA Corporate Presentation May 2022 Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are stat ...

Matinas BioPharma Holdings Inc. (NYSE:MTNB) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Peter Vozzo - Investor Relations Conference Call Participants Bert Hazlett - BTIG Operator Welcome to the Matinas BioPharma First Quarter 2022 Results Conference Call. At this time, all participants are in a listen-only m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2021 Earnings Conference Call March 8, 2022 8:30 AM ET Company Participants Peter Vozzo - Investor Relations Jerome Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Ferguson - Chief Medical Officer Conference Call Participants Robert Hazlett - BTIG Greg Fraser - Truist Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to ...